SFM
CRDF icon

Sphera Funds Management’s Cardiff Oncology CRDF Stock Holding History

Sphera Funds Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-40,000
Closed -$568K – 116
2020
Q3 		$568K Buy
+40,000
New +$264K 0.06% 91

Other funds holding CRDF

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Sphera Funds Management's CRDF Position: Q4 2020 in Review

Sphera Funds Management sold out of Cardiff Oncology (CRDF) in Q4 2020, closing a stake of 40,000 shares — an estimated $568K sold.

Sphera Funds Management first reported a position in CRDF in Q3 2020 and held it in 1 quarter. The position peaked at $568K in Q3 2020. 82 funds tracked by Wall St. Rank hold CRDF as of Q4 2020.

  • Sphera Funds Management reported no remaining Cardiff Oncology position as of Q4 2020 after selling out during the quarter.
  • Sphera Funds Management sold 40,000 Cardiff Oncology shares in Q4 2020, an estimated $568K.
  • Sphera Funds Management first reported a position in Cardiff Oncology in Q3 2020 and held it in 1 quarter.
  • Sphera Funds Management's Cardiff Oncology position peaked at $568K in Q3 2020.
  • 82 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2020.

Based on Sphera Funds Management's 13F filing for Q4 2020, filed 16 Feb 2021.